why choose us

Clinical Trials Search

Showing 12,630 of 132,366 result(s)
Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis

Status: Completed

Condition: Primary Axillary Hyperhidrosis

Interventions: Application of cream to each axilla

Date: 2023-04-27

Efficacy and Safety of Dingkundan Combined With Combination Oral Contraceptives in the Treatment of PCOS

Status: Completed

Condition: PCOS

Interventions:

The experimental group would be given DingKunDan, the subjects should take 3.5g each time, twice a day.

Subjects in the control group only ne

Date: 2023-04-27

Study of PULSAR-ICI +;- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

Status: Completed

Condition: Oligoprogressive

Interventions: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.

Date: 2023-04-27

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

Status: NOT_YET_RECRUITING

Condition: Lymphoblastic Leukemia

Interventions: Given orally (PO) or naso-gastrically (NG) or intravenously (IV).

Date: 2023-04-27

Linking Individuals Needing Care for Substance Use Disorders to Peer Coaches

Status: Completed

Condition: Substance Use Disorders

Interventions: Peer recovery coach (PRC) assessment of the participant's state of change, engage in motivational interviewing techniques, and link the participa

Date: 2023-04-27

Inflammation and Depression in People With HIV

Status: Completed

Condition: HIV

Interventions: Patients will receive baricitinib at a dose of 2 mg oral daily.

Date: 2023-04-27

Phase II Trial of Carboplatin +;- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers

Status: Completed

Condition: Metastatic Breast Cancer

Interventions: Carboplatin will be given AUC 6 IV q3 weeks for a maximum of 9 infusions.

Date: 2023-04-27

Study of PULSAR-ICI +;- IMSA101 in Patients With Oligometastatic NSCLC and RCC

Status: Completed

Condition: Oligometastatic Disease

Interventions: Intra-tumoral administration once weekly for the first three weeks of Cycle 1 (Days 1, 8 and 15) and then on Day 1 of Cycles 2 and 3.

Date: 2023-04-27

A Study of Invasive Hemodynamic for MACHD Registry

Status: Completed

Condition: Healthy

Interventions:

Date: 2023-04-27

Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions

Status: Completed

Condition: Wrinkles

Interventions: Subjects will receive 1-4 treatments at approximately 1 month intervals, but other intervals from 2 to 12 weeks may take place at the PI's discre

Date: 2023-04-27